Working… Menu

A 5 Year Clinical Investigation on Creos Xenoprotect (CXP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02373787
Recruitment Status : Terminated (Business reasons)
First Posted : February 27, 2015
Last Update Posted : November 13, 2017
Information provided by (Responsible Party):
Nobel Biocare

Brief Summary:
A 5-year clinical investigation on creos xenoprotect

Condition or disease Intervention/treatment Phase
Implant Device: creos xenoprotect Device: Bio-Gide Not Applicable

Detailed Description:
Randomized, prospective, multi-center study evaluating creos xenoprotect versus Bio-Gide® for guided bone regeneration in dehiscence defects

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 5 Year Clinical Investigation on Creos Xenoprotect
Study Start Date : July 2013
Actual Primary Completion Date : January 28, 2016
Actual Study Completion Date : October 2, 2017

Arm Intervention/treatment
Experimental: creos xenoprotect
resorbable collagen membrane
Device: creos xenoprotect
Implant placement with simultaneous bone augmentation

Active Comparator: Bio-Gide
Bio-Gide, resorbable collagen membrane
Device: Bio-Gide
resorbable collagen membrane

Primary Outcome Measures :
  1. To demonstrate bone regeneration through measurement of defect height [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Adverse events (AEs) [ Time Frame: 6 months ]

Other Outcome Measures:
  1. Membrane Dehiscence [ Time Frame: 6 months ]
  2. success and survival rates of implants [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Obtained informed consent from the subject.
  • The subject shall be at least 18 years of age and has passed cessation of growth.
  • The subject must be in such a physical and mental condition that a 5-year follow-up period can be carried out without foreseeable problems.
  • The patient is willing and able to comply with all study related procedures (such as exercising oral hygiene and attending all follow-up procedures).
  • The subject requires a single unit implant restoration with guided bone regeneration in bony defects in the anterior and premolar areas of maxilla or mandible.
  • If two or more site single unit implant restorations requiring bone augmentation are required, only one will be included in the study, the other site will be treated with standard of care.
  • The subject shall be healthy and compliant with good oral hygiene.
  • Full-mouth bleeding score (FMBS) lower than 25% [20].
  • Full-mouth plaque score (FMPI) lower than 20% [21].
  • The implant site is free from infection and extraction remnants.
  • The subject shall have a favourable and stable occlusal relationship.
  • Natural roots are adjacent to implant site.
  • The subject is suitable for a 2-stage surgical procedure. Secondary inclusion criteria at time of surgery
  • Sufficient bone volume at the implant site for placing a NobelReplace CC implant.
  • Initial implant stability as assessed by hand testing.
  • Defect size for guided bone regeneration:

Height ≥ 3 mm and ≤ 7 mm as assessed with a UNC15 periodontal probe.

Exclusion Criteria:

  • Previous bone augmentation at the implant site.
  • Extraction site less than 3 months after extraction.
  • Soft tissue grafting at implant placement, soft tissue grafting is allowed only at re-entry.
  • Health conditions, which do not permit the surgical treatment.
  • Any disorders in the planned implant area such as previous tumours, chronic bone disease or previous irradiation
  • Infections in the planned implantation site or adjacent tissue.
  • Acute, untreated periodontitis in the planned implantation site or adjacent tissue.
  • Any ongoing application of interfering medication (steroid therapy, bisphosphonate, etc).
  • Alcohol or substance abuse as noted in subject records or in subject history.
  • Heavy smoking (>10 cigarettes/day).
  • Uncontrolled diabetes, i.e. a subject with diagnosed diabetes that has a history of neglecting doctor's recommendations regarding treatment, food and alcohol intake or A1c level above 8%.
  • Severe bruxism or other destructive habits.
  • Pregnant or lactating women at the time of collagen membrane insertion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02373787

Layout table for location information
Praxisklinik der Zahnheilkunde am Luisenhospital
Aachen, Germany, 52064
Sponsors and Collaborators
Nobel Biocare
Layout table for investigator information
Study Director: Isabelle Arrighi, PhD Nobel Biocare Services AG
Layout table for additonal information
Responsible Party: Nobel Biocare Identifier: NCT02373787    
Other Study ID Numbers: T 186
First Posted: February 27, 2015    Key Record Dates
Last Update Posted: November 13, 2017
Last Verified: November 2017
Keywords provided by Nobel Biocare:
Collagen membrane
NobelReplace CC